On paper, a certain type of legal case may seem technical, but in reality, it is anything but. Among them is Monsanto Company v. Durnell. On the surface, the justices are faced with an almost numbingly procedural question: does a 1970s federal pesticide labeling statute nullify a Missouri jury’s decision? There’s something messier underneath. It is about a man who has lymphoma, a weedkiller that has been sprayed on half of the world’s farmland, and the question of who has the last say when scientists, regulators, and regular jurors examine the same evidence and come to different conclusions.
In January 2019, John Durnell filed a lawsuit against Monsanto, alleging that his frequent use of Roundup caused cancer. He was given $1.25 million by a St. Louis jury. The magnitude of what is truly at risk is concealed by that figure, which is small by mass-tort standards. His lawsuit is surrounded by about 100,000 similar ones, and Bayer, which bought Monsanto in 2018, has been losing settlements and court decisions for years. In an attempt to resolve the issue, the company proposed a $7.25 billion settlement in February. That number illustrates the level of anxiety in the Leverkusen boardroom.
| Case Information | Details |
|---|---|
| Case Name | Monsanto Company v. Durnell |
| Petitioner | Monsanto Company (subsidiary of Bayer AG) |
| Respondent | John L. Durnell |
| Product at Issue | Roundup weedkiller (active ingredient: glyphosate) |
| Original Court | Circuit Court of the City of St. Louis, Missouri |
| Jury Verdict | $1.25 million in compensatory damages |
| Appellate Ruling | Missouri Court of Appeals affirmed (February 2025) |
| Cert Granted | January 16, 2026 |
| Oral Argument Date | April 27, 2026 |
| Federal Statute | Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) |
| Total Related Lawsuits | Over 100,000 nationwide |
| Bayer’s Proposed Settlement | $7.25 billion (announced February 2026) |
| Decision Expected | Early July 2026 |
Monsanto makes a simple, almost elegant argument. States are not permitted to impose labeling requirements “in addition to or different from” federal ones, according to FIFRA, the 1947 federal law governing pesticide labels. Since 1974, the EPA has repeatedly reviewed glyphosate and determined that it is “not likely to be carcinogenic to humans.” The company questions how a Missouri jury could demand a cancer warning that the EPA has specifically declined to mandate. In a filing on behalf of the government, Solicitor General D. John Sauer referred to the alternative as a “State-by-State cacophony.” It’s a striking statement that isn’t totally incorrect.
However, Durnell’s attorneys have a different opinion. FIFRA forbids the sale of “misbranded” pesticides, and Missouri law forbids the sale of pesticides without “adequate warning.” They contend that the two standards are essentially two versions of the same sentence. Reading the briefs gives the impression that this case is more about deference than preemption doctrine—that is, whether a regulatory agency’s decision on science should preclude a jury’s decision on responsibility.
The background is also important. Glyphosate was categorized as “probably carcinogenic to humans” by the World Health Organization’s cancer research division in 2015. The EPA later rejected this conclusion after examining the same studies. One observer described that one disagreement as the beginning of a “tidal wave of litigation.” It also revealed an unsettling aspect of contemporary regulation: two capable groups of scientists can easily end up in different locations when closely examined.
Glyphosate was deemed critical to national security by President Trump in an executive order issued in February. This unusual intervention likely speaks more about farm-state politics than chemistry. As this develops, it’s difficult to ignore how a preemption-focused question keeps evolving into a more significant one about who determines what is safe and whether a Missouri jury can ever triumph over a Washington agency. Early July is when the decision is anticipated. Regardless of the outcome, the effects will go well beyond a single cannabis bottle.
